Dr. Bruce A. Decotiis, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
1673 Highway 88 West
Brick, NJ 08724
Who else practices at this address →
Ocean County includes primary care (21% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
NJ license 032368
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Injection, omalizumab, 5 mg | 2,100 | 19 |
| Professional service for preparation and provision of 1 or more antigens | 460 | 21 |
| Professional service for multiple injections of allergen | 286 | 92 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 126 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 57 | 50 |
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 35 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Brick, NJ | 37 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Brick, NJ | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $325 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $125 |
|---|---|
| Genentech USA, Inc. | $64.93 |
| Csl Behring | $61.11 |
| Adma Biomanufacturing LLC | $20.03 |
| Pharming Healthcare, Inc. | $19.80 |
| Greer Laboratories, Inc. | $18.59 |
| Paratek Pharmaceuticals, Inc. | $15.77 |
| Food and Beverage | $305 |
|---|---|
| Consulting Fee | $20.03 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Adma Biomanufacturing LLC Jul 29, 2025 | Consulting Fee | $20.03 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $161,879 in research payments for these studies, mostly to the institutions running them.
- A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Chiesi USA, Inc. · Completed · NCT05292586 - Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma Dominika
AstraZeneca UK Limited - A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
GlaxoSmithKline, LLC. - Registry of Asthma Patients Initiating DUPIXENT®
Regeneron Pharmaceuticals, Inc. · Completed · NCT04287621
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.